FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1984176340> ?p ?o ?g. }

• W1984176340 endingPage "38021" @default.
• W1984176340 startingPage "38015" @default.
• W1984176340 abstract "The small GTPase Rab2 requires atypical protein kinase C ι/λ (PKCι/λ) kinase activity to promote vesicle budding from normal rat kidney cell microsomes (Tisdale, E. J. (2000) Traffic 1, 702–712). The released vesicles lack anterograde-directed cargo but contain coat protein I (COPI) and the recycling protein p53/p58, suggesting that the vesicles traffic in the retrograde pathway. In this study, we have directly characterized the role of PKCι/λ in the early secretory pathway. A peptide corresponding to the unique PKCι/λ pseudosubstrate domain was introduced into an in vitro assay that efficiently reconstitutes transport of vesicular stomatitis virus glycoprotein from the endoplasmic reticulum to the cis-medial Golgi compartments. This peptide blocked transport in a dose-dependent manner. Moreover, normal rat kidney cells incubated with Rab2 and the pseudosubstrate peptide displayed abundant swollen or dilated vesicles that contained Rab2, PKCι/λ, β-COP, and p53/p58. Because Rab2, β-COP, and p53/p58 are marker proteins for pre-Golgi intermediates (vesicular tubular clusters,VTCs), most probably the swollen vesicles are derived from VTCs. Similar results were obtained when the assays were supplemented with kinase-dead PKCι/λ (W274K). Both the pseudosubstrate peptide and kinase-dead PKCι/λ in tandem with Rab2 caused sustained membrane association of PKCι/λ, suggesting that reverse translocation was inhibited. Importantly, the inhibitory phenotype of kinase-dead PKCι/λ was reversed by PKCι/λ wild type. These combined results indicate that PKCι/λ is essential for protein transport in the early secretory pathway and suggest that PKCι/λ kinase activity is required to promote Rab2-mediated vesicle budding at a VTC subcompartment enriched in recycling cargo. The small GTPase Rab2 requires atypical protein kinase C ι/λ (PKCι/λ) kinase activity to promote vesicle budding from normal rat kidney cell microsomes (Tisdale, E. J. (2000) Traffic 1, 702–712). The released vesicles lack anterograde-directed cargo but contain coat protein I (COPI) and the recycling protein p53/p58, suggesting that the vesicles traffic in the retrograde pathway. In this study, we have directly characterized the role of PKCι/λ in the early secretory pathway. A peptide corresponding to the unique PKCι/λ pseudosubstrate domain was introduced into an in vitro assay that efficiently reconstitutes transport of vesicular stomatitis virus glycoprotein from the endoplasmic reticulum to the cis-medial Golgi compartments. This peptide blocked transport in a dose-dependent manner. Moreover, normal rat kidney cells incubated with Rab2 and the pseudosubstrate peptide displayed abundant swollen or dilated vesicles that contained Rab2, PKCι/λ, β-COP, and p53/p58. Because Rab2, β-COP, and p53/p58 are marker proteins for pre-Golgi intermediates (vesicular tubular clusters,VTCs), most probably the swollen vesicles are derived from VTCs. Similar results were obtained when the assays were supplemented with kinase-dead PKCι/λ (W274K). Both the pseudosubstrate peptide and kinase-dead PKCι/λ in tandem with Rab2 caused sustained membrane association of PKCι/λ, suggesting that reverse translocation was inhibited. Importantly, the inhibitory phenotype of kinase-dead PKCι/λ was reversed by PKCι/λ wild type. These combined results indicate that PKCι/λ is essential for protein transport in the early secretory pathway and suggest that PKCι/λ kinase activity is required to promote Rab2-mediated vesicle budding at a VTC subcompartment enriched in recycling cargo. Protein kinase C (PKC) 1The abbreviations used are: PKC, protein kinase C; ER, endoplasmic reticulum; VTC(s), vesicular tubular cluster(s); GAPDH, glyceraldehyde-3-phosphate dehydrogenase; NRK, normal rat kidney; PBS, phosphate-buffered saline; GTPγS, guanosine 5′-O-(thiotriphosphate); β-COP, β-coat protein; endo H, endoglycosidase H; VSV-G, vesicular stomatitis virus G protein; ts, temperature-sensitive; ANOVA, analysis of variance. is a family of serine/threonine kinases that are classified into three major subfamilies: classical, novel, and atypical (1Blobe G. Stribling S. Obeid L. Hannun Y. Parker P. Pawson T. Cell Signalling. Cold Spring Harbor Laboratory, Cold Spring Harbor, NY1996: 213-249Google Scholar). The different isoenzymes probably possess unique functional properties since activation results in their translocation from the cytosol to distinct intracellular sites including the endoplasmic reticulum (ER) and the Golgi complex (2Parker P. Kour G. Marais R. Mitchell F. Pears C. Schaap D. Stabel S. Webster C. Mol. Cell. Endocr. 1989; 65: 1-11Crossref PubMed Scopus (236) Google Scholar, 3Nishizuka Y. Science. 1992; 258: 607-614Crossref PubMed Scopus (4232) Google Scholar, 4Toker A. Front. Biosci. 1998; 3: 1134-1147Crossref PubMed Google Scholar). PKC association with these organelles suggests that the kinase is a potential regulator of membrane traffic. In that regard, we have recently reported that PKCι/λ is essential for Rab2-stimulated β-coat protein (β-COP) recruitment to membranes (5Tisdale E.J. Traffic. 2000; 1: 702-712Crossref PubMed Scopus (41) Google Scholar). Furthermore, Rab2 required PKCι/λ kinase activity to generate vesicles enriched in PKCι/λ, β-COP, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and p53/p58 from normal rat kidney cell (NRK) microsomes (5Tisdale E.J. Traffic. 2000; 1: 702-712Crossref PubMed Scopus (41) Google Scholar). PKCι/λ is a member of the atypical subgroup of PKC that includes PKCζ. Unlike the other PKC isoforms, the atypical members do not contain the calcium binding domain and possess only one cysteine-rich region. The atypical subgroups of PKC are activated by the lipid mediator phosphatidylinositol 3,4,5-triphosphate and phosphatidic acid as well as by protein-protein interactions that direct the PKC in proximity of its cognate substrate (6Farese R.V. Am. J. Physiol. 2002; 283: E1-E11Crossref PubMed Scopus (147) Google Scholar). These specific interactions are necessary for the selective regulation of the different PKC isoforms. This subfamily of kinases plays a critical role in controlling cell growth and cell survival. The atypical subgroup of PKC binds proteins, which function as scaffolds that ultimately link signaling cascades with cytoskeletal rearrangement (7Berra E. Diaz-Meco M. Dominguez I. Municio M.M. Sanz L. Lozano J. Chapkin R. Moscat J. Cell. 1993; 74: 555-563Abstract Full Text PDF PubMed Scopus (343) Google Scholar, 8Wooten M.W. J. Neurosci. Res. 1999; 58: 607-611Crossref PubMed Scopus (77) Google Scholar, 9Moscat J. Diaz-Meco M. EMBO Rep. 2000; 1: 399-403Crossref PubMed Scopus (191) Google Scholar). Since it was important to determine the PKCι/λ substrate(s) that potentiated Rab2 activity in vesicle formation, studies were initiated to identify the phosphorylated protein(s). We found that GAPDH was efficiently phosphorylated by PKCι/λ and that GAPDH interacts directly with PKCι/λ through its regulatory domain (10Tisdale E.J. J. Biol. Chem. 2002; 277: 3334-3341Abstract Full Text Full Text PDF PubMed Scopus (131) Google Scholar). PKCι/λ-mediated phosphorylation of GAPDH is prevented by the peptide encoding for the unique pseudosubstrate region of PKCι/λ (10Tisdale E.J. J. Biol. Chem. 2002; 277: 3334-3341Abstract Full Text Full Text PDF PubMed Scopus (131) Google Scholar). The pseudosubstrate or autoinhibitory domain is present in the regulatory domain of all of the PKC isozymes and maintains phosphoinositide-dependent kinase 1-phosphorylated and autophosphorylated cytosolic PKC in an inactive conformation by blocking the protein-substrate binding site (11Dutil E. Newton A. J. Biol. Chem. 2000; 275: 10697-10701Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar). Translocation of this catalytically competent but inactive PKC to membrane results in the removal of the pseudosubstrate domain, allowing substrate access to the active site and its subsequent phosphorylation. The same consequence of kinase inactivation occurs in the presence of peptidomimetics of the pseudosubstrate sequence. In fact, pseudosubstrate peptides have been used successfully to determine the substrate specificity of PKC as well as to define the biological response of the phosphorylated substrate (12Alexander D. Hexham J. Lucas S. Graves J. Cantrell D. Biochem. J. 1989; 260: 893-901Crossref PubMed Scopus (48) Google Scholar, 13Eichholtz T. Alblas J. Overveld M. Moolenaar W. Ploegh H. FEBS Lett. 1990; 261: 147-150Crossref PubMed Scopus (20) Google Scholar, 14Ward N. O'Brian C. Biochemistry. 1993; 32: 11903-11909Crossref PubMed Scopus (77) Google Scholar). Unlike most PKC inhibitors that interfere with the function of multiple kinases, these peptides have the advantage of specifically interfering with the activity of a particular PKC isozyme because of the fact that the pseudosubstrate amino acid sequence differs considerably among the subfamilies (15Hug H. Sarre T. Biochem. J. 1993; 291: 329-342Crossref PubMed Scopus (1218) Google Scholar). In this study, we directly characterized the role of PKCι/λ in the early secretory pathway by introducing a synthetic peptide corresponding to the PKCι/λ pseudosubstrate region into a battery of biochemical and morphological assays. We found that this peptide was a potent inhibitor of VSV-G transport from the ER to the Golgi complex. Permeabilized NRK cells treated with Rab2 and the PKCι/λ peptide accumulated dilated vesicular structures that labeled with an antibody to PKCι/λ, Rab2, p53/p58, and β-COP but contained a negligible amount of VSV-G. Based on our previous findings, this labeling profile is highly suggestive that the swollen vesicular structures are a Rab2-regulated VTC subcompartment. A quantitative microsomal binding assay indicated that membranes incubated with Rab2 and the pseudosubstrate peptide showed a constant level of membrane-associated PKCι/λ, indicating that reverse translocation of the kinase was delayed. Because the pseudosubstrate peptide prohibits PKCι/λ-dependent phosphorylation and Rab2-mediated retrograde-vesicle formation and therefore mimics the effect of kinase-dead PKCι/λ (W274K), we characterized the PKCι/λ mutant in the transport and morphological assay. The kinase-dead mutant blocked VSV-G transport to the Golgi complex. Furthermore, permeabilized NRK cells incubated with the PKCι/λ mutant contained vesicles similar to those observed in cells treated with the pseudosubstrate peptide. Importantly, PKCι/λ wild type markedly reversed the inhibition in VSV-G transport and the phenotype produced by kinase-dead PKCι/λ. We propose that Rab2 stimulates PKCι/λ recruitment to a VTC subcompartment. The PKCι/λ pseudosubstrate peptide causes the sustained binding of PKCι/λ to pre-Golgi intermediates by preventing reverse translocation that requires functional PKCι/λ kinase activity (16Feng X. Becker K. Stribling S. Peters K. Hannun Y. J. Biol. Chem. 2000; 275: 17024-17034Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar, 17Signorelli P. Luberto C. Hannun Y. FASEB J. 2001; 15: 2401-2414Crossref PubMed Scopus (36) Google Scholar). The VTC subcompartment becomes “swollen” because Rab2-mediated retrograde-vesicle release is blocked in the absence of kinase activity by PKCι/λ (K274W) or inhibition by the pseudosubstrate peptide. This causes VTCs to be stalled in their forward movement to the Golgi complex because of the inability to recycle proteins to the ER and transfer anterograde-directed cargo to the late compartments of the secretory pathway. Materials and Methods—PKCι/λ pseudosubstrate peptide (SIYRRGARRWRKLYCAN), scrambled PKCι/λ peptide (WRICGNKARLRRYYSAR), PKCα pseudosubstrate peptide (RFARKGALRQKNVHEVKD), and PKCγ pseudosubstrate peptide (LFCRKGALRQKVVHEVK) were synthesized at the University of Michigan Protein and Carbohydrate Structure facility (Ann Arbor, MI). The cDNA to PKCι was a gift from Dr. Trevor Biden (Garvan Institute of Medical Research, Sydney, Australia). Dr. Alan Tartakoff (Case Western Reserve University, Cleveland, OH) provided the monoclonal antibody (6F4C5) to the Golgi complex. Analysis of Transport in Vitro—NRK cells were infected for 4 h with the temperature-sensitive VSV strain ts045 and then biosynthetically radiolabeled with 100 μCi of trans-[35S] (specific activity 1192 Ci/mmol, ICN Biomedicals, Irvine, CA) for 10 min at the restrictive temperature (39.5 °C) to accumulate the VSV-G mutant protein in the ER. The cells were then perforated by swelling and scraping and were employed in the ER to cis-medial Golgi transport assay as described previously (18Beckers C.J.M. Keller D.S. Balch W.E. Cell. 1987; 50: 523-534Abstract Full Text PDF PubMed Scopus (197) Google Scholar). Transport reactions were performed in a final volume of 40 μl in a buffer that contains 25 mm Hepes-KOH, pH 7.2, 75 mm KOAc, 2.5 mm MgOAc, 5 mm EGTA, 1.8 mm CaCl2,1mm N-acetylglucosamine, an ATP regeneration system (1 mm ATP, 5 mm creatine phosphate, and 0.2 IU of rabbit muscle creatine phosphokinase), 5 μl of rat liver cytosol (∼25–30 μg of total protein), and 5 μl of semi-intact cells (∼5 × 107 cells/ml) resuspended in 50 mm Hepes-KOH, and 90 mm KOAc, pH 7.2. The reactions were incubated at 32 °C for 60 min, and then transferred to ice to terminate transport. Membranes were pelleted, solubilized in buffer, digested with endoglycosidase H (endo H), and then analyzed by SDS-PAGE and fluorography. The fraction of ts045 VSV-G protein processed to the endo H-resistant forms was quantitated by a Storm PhosphorImager (Amersham Biosciences). Morphological Assay, Indirect Immunofluorescence—NRK cells plated on coverslips were infected with ts045 at 39.5 °C for 2–3 h and then shifted to ice and permeabilized with digitonin (20 μg/ml) as outlined previously (19Plutner H. Davidson H.W. Saraste J. Balch W.E. J. Cell Biol. 1992; 119: 1097-1116Crossref PubMed Scopus (175) Google Scholar, 20Tisdale E.J. Balch W.E. J. Biol. Chem. 1996; 271: 29372-29379Abstract Full Text Full Text PDF PubMed Scopus (108) Google Scholar). Coverslips with permeabilized cells were inverted and placed in tissue culture wells that contained the transport mixture described above, preincubated on ice for 15 min without or with Rab2 and PKCι/λ pseudosubstrate peptide, His6-PKCι/λ wild type, or His6-PKCι/λ (K274W), and then incubated for 40 min at 32 °C. To terminate transport, the cells were transferred to ice and fixed in 3% formaldehyde/phosphate-buffered saline (PBS) for 10 min. To detect intracellular VSV-G, cells were re-permeabilized with 0.05% saponin in PBS, 5% normal goat serum for 10 min, washed with PBS, and then incubated for 30 min with a monoclonal antibody specific for the VSV-G protein cytoplasmic tail (P5D4) (Sigma) or with an affinity-purified polyclonal antibody to β-COP (EAGE) (21Tisdale E.J. Jackson M.R. J. Biol. Chem. 1998; 273: 17269-17277Abstract Full Text Full Text PDF PubMed Scopus (44) Google Scholar) or a polyclonal antibody to p53/p58 (22Tisdale E.J. Plutner H. Matteson J. Balch W.E. J. Cell Biol. 1997; 137: 581-593Crossref PubMed Scopus (77) Google Scholar) or a monoclonal antibody to PKCι/λ (Transduction Laboratories, Lexington, KY) or an anti-His-Tag (27E8) monoclonal antibody (Cell Signaling Technology, Beverly, MA) or an affinity-purified polyclonal antibody to Rab2. Cells were then washed with PBS, stained for 30 min with Alexa Fluor 549 chicken anti-rabbit antibody or Alexa Fluor 488 chicken anti-mouse antibody, washed, mounted in Prolong antifade (Molecular Probes, Eugene, OR), and then viewed by Confocal light microscopy with a Zeiss LSM 510 confocal microscope (LSM 510) located at the John D. Dingle Veterans Administration Medical Center (Detroit, MI). The lasers and available lines are as follows: Enterprise (UV, 351 and 364 nm), Argon (458, 488, and 514 nm), HeNe1 (543 nm), and HeNe2 (633 nm). The confocal microscope was operated with pin-hole settings between 1.1 and 1.4 Airy units in each of the fluorescence channels. Images were recorded at 2048 × 2048 pixels × 12 bits/channel and then viewed and converted to TIFF using the Zeiss LSM Viewer software and processed for printing with Adobe Photoshop 6.0. Quantitative Membrane Binding Assay—NRK cells were washed three times with ice-cold PBS. The cells were scraped off the dish with a rubber policeman into 10 mm Hepes, pH 7.2, and 250 mm mannitol and then broken with 15 passes through a 27-gauge syringe. The broken cells were pelleted at 500 × g for 10 min at 4 °C, and the supernatant was re-centrifuged at 20,000 × g for 20 min at 4 °C. The pellet containing ER, pre-Golgi, and Golgi membranes was washed with 1 m KCl in 10 mm Hepes, pH 7.2, for 15 min on ice and then centrifuged at 20,000 × g for 20 min at 4 °C. The membranes were resuspended in 10 mm Hepes, pH 7.2, and 250 mm mannitol and employed in the binding reaction as described previously (21Tisdale E.J. Jackson M.R. J. Biol. Chem. 1998; 273: 17269-17277Abstract Full Text Full Text PDF PubMed Scopus (44) Google Scholar, 23Aridor M. Weissman J. Bannykh S. Nuoffer C. Balch W.E. J. Cell Biol. 1998; 141: 61-70Crossref PubMed Scopus (247) Google Scholar). Membranes (30 μg of total protein) were added to a reaction mixture that contained 27.5 mm Hepes, pH 7.2, 2.75 mm MgOAc, 65 mm KOAc, 5 mm EGTA, 1.8 mm CaCl2, 1 mm ATP, 5 mm creatine phosphate, and 0.2 units of rabbit muscle creatine kinase. PKCι/λ pseudosubstrate peptide and Rab2 protein were added to obtain the final concentration as indicated under “Results,” and the reaction mixture was incubated on ice for 15 min. Rat liver cytosol (50 μg) and 2.0 μm GTPγS were then added, and the reactions shifted to 37 °C and incubated for 10 min. The binding reaction was terminated by transferring the samples to ice and then was centrifuged at 20,000 × g for 10 min at 4 °C. The pellet was resuspended in sample buffer, separated by SDS-PAGE, and transferred to nitrocellulose membrane in 25 mm Tris, pH 8.3, 192 mm glycine, and 20% methanol. The membrane was blocked in Tris-buffered saline, which contained 5% nonfat dry milk and 0.5% Tween 20, incubated with an affinity-purified polyclonal antibody made to the EAGE peptide of β-COP (21Tisdale E.J. Jackson M.R. J. Biol. Chem. 1998; 273: 17269-17277Abstract Full Text Full Text PDF PubMed Scopus (44) Google Scholar) or a monoclonal antibody to GAPDH (Chemicon, Temecula, CA) or a monoclonal antibody to PKCι/λ (Transduction Laboratories) or an anti-phosphoserine monoclonal antibody (Calbiochem), washed, further incubated with a horseradish peroxidase-conjugated anti-rabbit or anti-mouse antibody (Pierce), developed with ECL (Amersham Biosciences), and then quantitated by densitometry. Purification of Recombinant Wild Type and Kinase-dead PKCι/λ— The transient expression of PKCι/λ and PKCι/λ (K274W) was performed as described previously (24Tisdale E.J. Bourne J.R. Khosravi-Far R. Der C.J. Balch W.E. J. Cell Biol. 1992; 119: 749-761Crossref PubMed Scopus (423) Google Scholar). HeLa cells (3 × 106/10 cm dish × 5) were infected with a vaccinia T7 RNA polymerase recombinant virus (vTF7-3) for 30 min and then transfected with 20 μg of pcDNA4/HisMax-TOPO PKCι/λ wild type or PKCι/λ (K274W), which had been premixed in LipofectACE (Invitrogen). 8 h post-transfection, the cells were detached from the dish with PBS/EDTA and washed once with 10/18 (10 mm KOAc, 18 mm Hepes, pH 7.2). The cells were resuspended in 10/18 containing protease inhibitors (10 μm aprotinin, 10 μm 1-chloro-3-tosylamido-7-amino-2-heptanone, 1 μg/ml chymotrypsin, 0.1 μm pepstatin), swollen on ice for 10 min, and then homogenized by 20 passes through a 27-gauge needle after which the concentration was adjusted to 25 mm KOAc, 125 mm Hepes. The nuclei were removed by centrifugation for 5 min at 500 × g, and the post-nuclear supernatant was centrifuged at 100,000 × g for 60 min at 4 °C in a micro-ultracentrifuge system (Sorval, Discovery M120). The supernatant that contained overexpressed His6/Xpress-tagged PKCι/λ and PKCι/λ (K274W) was then applied to a 2-ml column of Ni2+-nitrilotriacetic acid-agarose (Qiagen, Valencia, CA) equilibrated in Buffer A (10 mm Hepes, pH 7.9, 5 mm MgCl2, 0.1 mm EDTA, 50 mm NaCl, 0.8 mm imidazole). The column was washed with 10 volumes of Buffer A containing 8 mm imidazole. The tagged protein was eluted with Buffer A supplemented with 80 mm imidazole. An aliquot of the collected fractions was analyzed by SDS-PAGE and immunoblotted with anti-Xpress monoclonal antibody (Invitrogen). His6/Xpress-tagged PKCι/λ and PKCι/λ (K274W) enriched fractions were pooled and concentrated, and the protein concentration was determined by Micro BCA protein assay reagent (Pierce). Purification of recombinant Rab2 and in vitro prenylation was performed as described previously (25Tisdale E.J. Mol. Biol. Cell. 1999; 10: 1837-1849Crossref PubMed Scopus (65) Google Scholar). PKCι/λ Pseudosubstrate Peptide Inhibits ER to Golgi Transport—Although PKC activators and inhibitors are routinely used to demonstrate the requirement for PKC, few studies have shown that PKC is directly involved in intracellular transport. To address this issue, we have introduced a synthetic peptide specific to the PKCι/λ pseudosubstrate domain into an in vitro transport assay (18Beckers C.J.M. Keller D.S. Balch W.E. Cell. 1987; 50: 523-534Abstract Full Text PDF PubMed Scopus (197) Google Scholar). This peptide interferes with PKCι/λ activity without modulating the kinase activity of other PKC isoenzymes (26House C. Kemp B. Science. 1987; 238: 1726-1728Crossref PubMed Scopus (791) Google Scholar, 27Laudanna C. Mochly-Rosen D. Liron T. Constantin G. Butcher E. J. Biol. Chem. 1998; 273: 30306-30315Abstract Full Text Full Text PDF PubMed Scopus (209) Google Scholar). Tissue culture cells were first infected with ts045 VSV, a virus that encodes for a glycoprotein (G protein) with a thermoreversible defect that results in ER retention at 39.5 °C (28Gallione C. Rose J.K. J. Virol. 1985; 54: 374-382Crossref PubMed Google Scholar). The plasma membrane of these cells was perforated to release soluble content and then incubated at 32 °C in the presence of cytosol and ATP to initiate export of ts045 VSV-G from the ER. This semi-intact cell assay measures transport of ts045 VSV-G protein by following the processing of the two N-linked oligosaccharides to endo H-resistant forms indicative of transport to the cis-medial Golgi stacks. Fig. 1 shows that ts045 VSV-G transport from the ER to the Golgi complex was blocked in cells treated with increasing concentrations of the PKCι/λ pseudosubstrate peptide. Transport was reduced by 50% at a pseudosubstrate peptide concentration of 25 μm, whereas a randomized peptide had no effect on transport. These results indicate that PKCι/λ kinase activity is essential for ER to Golgi transport. We then determined the kinetics of inhibition of the PKCι/λ pseudosubstrate peptide relative to the transport block imposed by the addition of Rab2 (13-mer). This peptide made to the Rab2 amino terminus arrests VSV-G transport from the VTC (20Tisdale E.J. Balch W.E. J. Biol. Chem. 1996; 271: 29372-29379Abstract Full Text Full Text PDF PubMed Scopus (108) Google Scholar). ts045 VSV-G-infected NRK cells were incubated at 32 °C and at the indicated time (Δt), transferred to ice (control) or supplemented with 50 μm PKCι/λ pseudosubstrate peptide or with 75 μm Rab2 (13-mer), and then incubated for a total of 60 min. This protocol allows any VSV-G that has migrated past the Rab2 or PKCι/λ-requiring step to continue migration to the cis-Golgi compartment. Therefore, the fraction of VSV-G processed to endo H resistance will depend on the amount of the reporter molecule that has transported beyond the Rab2 and the PKCι/λ-sensitive step at the time of their addition. In control cells, VSV-G endo H-resistant forms were detected after a 15-min lag (Fig. 1B). Within ∼20 min of incubation, 50% of the VSV-G protein was processed, indicating migration to the Golgi complex. In contrast, cells treated with the pseudosubstrate peptide were blocked in transport ∼5 min before the processing of VSV-G to endo H-resistant forms, and by 20 min of incubation, 65% VSV-G had transported through the pseudosubstrate-sensitive step. This temporal site of inhibition by PKCι/λ peptide occurs immediately following the block that occurs in the presence of Rab2 (13-mer). In both cases, the block in transport by pseudosubstrate peptide and Rab2 preceded the processing of VSV-G to endo H-sensitive forms by 5–10 min. This result indicates that PKCι/λ acts downstream of Rab2 but is required prior to cargo delivery to the Golgi complex. NRK Cells Treated with Pseudosubstrate Peptide Accumulate Swollen Vesicles—To define the morphological site of ts045 VSV-G accumulation in response to the pseudosubstrate peptide, NRK cells were infected with the virus for 3 h at the nonpermissive temperature to restrict VSV-G to the ER. The cells were then permeabilized and incubated in the absence or presence of Rab2 and PKCι/λ pseudosubstrate peptide for 40 min at 32 °C, and the distribution of VSV-G was examined by confocal microscopy. Controls cells efficiently transported the reporter molecule to the Golgi complex (Fig. 2a) as did cells treated with the scrambled peptide (Fig. 2b). Consistent with the biochemical data, cells incubated with the pseudosubstrate peptide failed to transport VSV-G to the Golgi complex. Instead, VSV-G accumulated in a collar-like structure composed of small vesicular elements that ringed the nucleus (Fig. 2c). This staining pattern is similar to that observed when cells are incubated with constitutively activated Rab2 (Q65L) and with our affinity-purified anti-GAPDH polyclonal antibody (25Tisdale E.J. Mol. Biol. Cell. 1999; 10: 1837-1849Crossref PubMed Scopus (65) Google Scholar, 29Tisdale E.J. J. Biol. Chem. 2001; 276: 2480-2486Abstract Full Text Full Text PDF PubMed Scopus (116) Google Scholar). When these pseudosubstrate peptide-treated cells were costained with an anti-p53/p58 polyclonal antibody, a nominal degree of co-localization was observed, indicating that VSV-G did not transport to the VTC (Fig. 2d). Interestingly, p53/58 was found on swollen vesicles that were largely absent from the cell periphery but concentrated near and surrounding the nucleus (Fig. 2f). These swollen vesicles displayed a considerable degree of co-localization with anti-PKCι/λ antibody and antibodies to Rab2 (Fig. 2e), p53/p58 (Fig. 2f), and β-COP (Fig. 2g). The presence of three VTC marker proteins suggests that the structures are derived from pre-Golgi intermediates (29Tisdale E.J. J. Biol. Chem. 2001; 276: 2480-2486Abstract Full Text Full Text PDF PubMed Scopus (116) Google Scholar, 30Saraste J. Svensson K. J. Cell Sci. 1991; 100: 415-430Crossref PubMed Google Scholar). From our earlier studies, we reported that PKCι/λ interacted directly with GAPDH. For this reason, the peptide-treated cells were also stained with antibodies specific to GAPDH to determine whether the pseudosubstrate peptide affected its distribution. Unlike PKCι/λ that is found on the dilated vesicles, a weak co-localization signal was observed for GAPDH (Fig. 2h). Importantly, we found no change in Golgi structure after incubation with the pseudosubstrate peptide (Fig. 2i) nor did we find that the swollen vesicles stained with a monoclonal antibody to protein-disulfide isomerase, a marker of the ER (Fig. 2i, inset). To learn whether there was enhanced recruitment of those proteins detected on the swollen vesicles in response to treatment with Rab2 and PKCι/λ pseudosubstrate peptide, a quantitative binding assay was employed (5Tisdale E.J. Traffic. 2000; 1: 702-712Crossref PubMed Scopus (41) Google Scholar, 21Tisdale E.J. Jackson M.R. J. Biol. Chem. 1998; 273: 17269-17277Abstract Full Text Full Text PDF PubMed Scopus (44) Google Scholar). For this assay, microsomes were prepared from NRK cell homogenates and washed with 1 m KCL to remove peripherally associated proteins. These membranes were preincubated with buffer for 15 min on ice in the absence or presence of 50 ng of Rab2 and with increasing concentrations of the PKCι/λ pseudosubstrate peptide. The reaction was then supplemented with rat liver cytosol and GTPγS and incubated at 37 °C for 10 min to promote binding of soluble components. To stop the reaction, membranes were pelleted by centrifugation at 20,000 × g and the pellet was separated by SDS-PAGE and immunoblotted. A marked increase in membrane-associated PKCι/λ was observed after incubation with Rab2 and dependent on the pseudosubstrate peptide concentration (Fig. 3A). As predicted, there was a dose-dependent increase in membrane-associated β-COP (Fig. 3B), whereas the amount of GAPDH bound to membranes decreased with increasing concentrations of the peptide (Fig. 3C). This result is consistent with our previous findings in which the pseudosubstrate peptide blocked Rab2-stimulated GAPDH recruitment to membrane by interfering with PKCι/λ-GAPDH interaction (10Tisdale E.J. J. Biol. Chem. 2002; 277: 3334-3341Abstract Full Text Full Text PDF PubMed Scopus (131) Google Scholar). Moreover, we found a concomitant decrease in the amount of phospho-GAPDH bound to the membranes indicating that the pseudosubstrate peptide was inhibiting the kinase activity of the recruited PKCι/λ (Fig. 3D). The enhanced recruitment of PKCι/λ and β-COP was specific to the PKCι/λ peptide. We did not observe any change in the level of these proteins when the assay was supplied with the scrambled peptide or with pseudosubstrate peptides made to PKCα or to PKCγ. These two isoforms were studied because both were found on NRK microsomes used in the binding assay (5Tisdale E.J. Traffic. 2000; 1: 702-712Crossref PubMed Scopus (41) Google Scholar). A time course was performed to determine the rate of PKCι/λ binding to membranes treated with the pseudosubstrate peptide and Rab2. We knew from our earlier studies that Rab2 stimulated rapid translocation of PKCι/λ to membranes within minutes of addition. Longer incubation times lead to a progressive loss of PKCι/λ from the membrane due to the release of Rab2-generated vesicles containing PKCι/λ (5Tisdale E.J. Traffic. 2000; 1: 702-712Crossref PubMed Scopus (41) Google Scholar). As shown in Fig. 4, PKCι/λ was recruited to membranes by Rab2 and pseudosubstrate peptide at a rate comparable to membranes treated only with Rab2. However, unlike microsomes incubated only with Rab2, there was no loss of PKCι/λ from the membranes with increasing times of incubation. A similar result was obtained when the assay was performed with kinase-dead PKCι/λ and Rab2. These results indicate that VTC-derived retrograde-vesicle release was inhibited and are consistent with our previous finding that PKCι/λ kinase activity is essential for Rab2-mediated vesicle formation. Kinase-Dead PKCι/λ Interferes with ER to Golgi Transport—To further demonstrate that PKCι/λ was required for transport in the early secretory pathway, we introduced purified wild type His6-PKCι/λ and kinase-dead His6-PKCι/λ (K275W) into the in vitro transport assay. Kinase-dead PKCι/λ inhibited the processing of VSV-G to endo H-resistant forms in a concentration-dependent manner (Fig. 5A). Transport was reduced by 50% at a mutant protein concentration of 75 ng. This reduction is significant because the mutant protein must compete with endogenous PKCι/λ wild type for limited binding sites on VTCs. Importantly, PKCι/λ wild type reversed the block in transport by the mutant protein (Fig. 5A). Kinase-dead PKCι/λ was then introduced into the morphological assay to determine whether the mutant protein caused a phenotype similar to cells treated with the pseudosubstrate peptide. NRK cells were first permeabilized and then incubated in the absence or presence of Rab2 and His6-PKCι/λ wild type or His6-PKCι/λ (K275W) for 45 min at 32 °C. In cells incubated with His6-PKCι/λ, anti-His6 monoclonal antibody labeled tubular-like beaded structures largely concentrated around the nucleus and near the Golgi complex (Fig. 5B). These cells did not appear to contain the swollen vesicles that were present in pseudosubstrate peptide-treated cells. However, permeabilized cells incubated with kinase-dead His6-PKCι/λ displayed enlarged vesicles co-stained with anti-His6 monoclonal antibody and anti-p53/p58 that were juxtanuclear in location and similar in size but less abundant compared with cells incubated with the pseudosubstrate peptide (Fig. 5B). This phenotype was lost when cells were co-incubated with PKCι/λ wild type and kinase-dead protein (Fig. 5B). In this case, PKCι/λ distribution was identical to cells treated with the wild type kinase. These combined results are highly suggestive that inactive PKCι/λ is a contributing factor to the formation and accumulation of swollen vesicles that most likely correspond to a VTC subcompartment. The PKC enzyme family contains in the C1 domain an autoinhibitory pseudosubstrate sequence that maintains the enzyme in the inactive form. This allows the substrate to be phosphorylated by the kinase after translocation to a specific intracellular membrane where the pseudosubstrate is removed by lipid activators (11Dutil E. Newton A. J. Biol. Chem. 2000; 275: 10697-10701Abstract Full Text Full Text PDF PubMed Scopus (82) Google Scholar). A similar effect occurs in the presence of exogenous pseudosubstrate sequences. Unlike PKC inhibitors that are generally nonspecific, pseudosubstrate peptides are the most selective tools to interfere with kinase activity. These peptides permit modulation of cell activities through direct interaction with a PKC isoform. We found that the PKCι/λ pseudosubstrate peptide was a potent inhibitor of VSV-G transport from the ER to the Golgi complex, whereas the addition of a randomized peptide had no effect. The arrest in VSV-G transport also occurred when the assay was supplemented with kinase-dead PKCι/λ. The pseudosubstrate peptide and kinase-dead PKCι/λ have previously been shown to efficiently block PKCι/λ phosphorylation of GAPDH in an in vitro kinase assay and inhibit Rab2-mediated vesicle release from NRK microsomes (10Tisdale E.J. J. Biol. Chem. 2002; 277: 3334-3341Abstract Full Text Full Text PDF PubMed Scopus (131) Google Scholar). Therefore, the inhibition by the PKCι/λ pseudosubstrate peptide is specific and like PKCι/λ (K274W) is because of the absence of PKCι/λ phosphorylation activity that is required for transport in the early secretory pathway. Moreover, our results indicate that PKCι/λ kinase activity is required for reverse translocation. NRK microsomes treated with Rab2 and pseudosubstrate peptide or kinase-dead PKCι/λ showed both enhanced recruitment and sustained PKCι/λ membrane association. Similar results have been reported for PKCβII in which the kinase-inactive enzyme exhibits reduced dissociation from membranes (16Feng X. Becker K. Stribling S. Peters K. Hannun Y. J. Biol. Chem. 2000; 275: 17024-17034Abstract Full Text Full Text PDF PubMed Scopus (69) Google Scholar, 32Parekh D. Ziegler W. Parker P. EMBO J. 2000; 19: 496-503Crossref PubMed Scopus (513) Google Scholar). Importantly, VSV-G transport inhibition mediated by kinase-dead PKCι/λ was reversed by PKCι/λ wild type. A dramatic change in cell morphology was observed in PKCι/λ peptide and kinase-dead incubated cells. These cells displayed swollen vesicles that labeled with antibodies to PKCι/λ, β-COP, Rab2, and p53/p58. This phenotype was in direct contrast to cells incubated with recombinant PKCι/λ wild type, which contained anti-His6-labeled tubular-like elements in proximity to the Golgi complex. In some cases, the entities had a beaded-like appearance and may define domains actively involved in protein sorting and in the initial stage of vesicle budding (33Horstmann H. Ng C.P. Tang B. Hong W. J. Cell Sci. 2002; 115: 4263-4273Crossref PubMed Scopus (49) Google Scholar). Importantly, PKCι/λ wild type prevented the formation of swollen vesicles by kinase-dead PKCι/λ. This observation further indicates that the swollen structures are the product of dysfunctional PKCι/λ. Because p53/p58, β-COP, and Rab2 are marker proteins for pre-Golgi intermediates, the swollen entities are most probably derived from VTCs. VTCs are composed of small vesicles and tubules and represent transport intermediates between the ER and the Golgi complex (34Balch W.E. McCaffery J.M. Plutner H. Farquhar M.G. Cell. 1994; 76: 841-852Abstract Full Text PDF PubMed Scopus (334) Google Scholar). These structures are the first site of segregation of the anterograde and retrograde pathways and thereby sort and recycle resident proteins from itinerate proteins destined for secretion. This sorting process results in domains highly enriched in retrograde-directed cargo and domains enriched in secretory cargo (35Martinez-Menarguez J.A. Geuze H. Slot J. Klumperman J. Cell. 1999; 98: 81-90Abstract Full Text Full Text PDF PubMed Scopus (261) Google Scholar). For this reason, a negligible amount of VSV-G, which traffics in the anterograde pathway, was detected in the swollen vesicles. The time of addition experiments performed in this study indicate that the pseudosubstrate peptide blocks VSV-G transport after the site of Rab2 (13-mer) action and before cargo transit to the Golgi complex. Therefore, it is possible that the swollen vesicles observed in kinase-dead and pseudosubstrate peptide-treated cells result from inhibition of retrograde-vesicle release from a VTC subcompartment enriched in recycling proteins, an event that requires PKCι/λ kinase activity. Interestingly, many of the Rab2-PKCι/λ pseudosubstrate peptide-induced swollen structures contain a membrane “patch” where Rab2 and Rab2 effectors co-localized (Fig. 2e, inset). Since anterograde and retrograde transport are coupled, the inability to retrieve essential trafficking components from the VTC to the ER caused the arrest in VSV-G transport. Since GAPDH is a substrate for PKCι/λ and is required for ER to Golgi transport, it was conceivable that phospho-GAPDH was the essential phosphoprotein required for vesicle release from the VTC. However, our affinity-purified anti-GAPDH polyclonal antibody, which efficiently blocks ER to Golgi transport, does not affect Rab2-stimulated vesicle formation. Although GAPDH is required for transport in the early secretory pathway, membrane-associated GAPDH is not essential for vesicle formation, indicating that GAPDH is not a critical component of the budding machinery. Instead, we believe that phospho-GAPDH is part of a protein complex that assembles on a VTC subcompartment in response to Rab2. This complex would serve as an export site to coordinate events required for retrograde-vesicle budding and microtubule nucleation. The observation that phospho-GAPDH is not required for vesicle release presents the possibility that there is an additional PKCι/λ substrate(s) located on the VTC that is not detected because phosphorylation results in membrane dissociation. This interpretation would be consistent with the observation that numerous transport-related proteins undergo cycles of phosphorylation-dephosphorylation, which influences the protein cellular location and modulates their activity (36Slepnev V. Ochoa G.-C. Butler M. Grabs D. DeCamilli P. Science. 1998; 281: 821-824Crossref PubMed Scopus (275) Google Scholar, 37Bailly E. McCaffrey M. Touchot N. Zahraoui A. Goud B. Bornens M. Nature. 1991; 350: 715-718Crossref PubMed Scopus (131) Google Scholar, 38van der Sluijs P. Hull M. Webster P. Male P. Goud B. Mellman I. Cell. 1992; 70: 729-740Abstract Full Text PDF PubMed Scopus (517) Google Scholar). From these combined results, we propose that Rab2 binding to the VTC subdomain initiates a cascade of events that results in the recruitment of PKCι/λ, GAPDH, and other unidentified effectors from the cytosol. Rab2 in complex with its effectors defines the site of retrograde-vesicle budding from VTCs. PKCι/λ activation is a critical event that results in the phosphorylation of GAPDH and signals the downstream recruitment of COPI, which ultimately leads to the release of vesicles enriched in recycling components. Because VTCs are the secretory pathways counterpart to endosomes, the suggestion that Rab2 binds to and promotes membrane recycling from a VTC subcompartment is consistent with the finding that Rab5, Rab4, and Rab11 associate with endosome microdomains and regulate sequential transport events (39De Renzis S. Sonnichsen B. Zerial M. Nat. Cell Biol. 2002; 4: 124-133Crossref PubMed Scopus (265) Google Scholar)" @default.
• W1984176340 created "2016-06-24" @default.
• W1984176340 creator A5037677450 @default.
• W1984176340 creator A5053608387 @default.
• W1984176340 creator A5056746618 @default.
• W1984176340 creator A5061438758 @default.
• W1984176340 date "2003-09-01" @default.
• W1984176340 modified "2023-09-30" @default.
• W1984176340 title "Atypical Protein Kinase C Plays a Critical Role in Protein Transport from Pre-Golgi Intermediates" @default.
• W1984176340 cites W148785554 @default.
• W1984176340 cites W1548266878 @default.
• W1984176340 cites W1779110547 @default.
• W1984176340 cites W1852712855 @default.
• W1984176340 cites W1965260691 @default.
• W1984176340 cites W1968006498 @default.
• W1984176340 cites W1969963064 @default.
• W1984176340 cites W1970689030 @default.
• W1984176340 cites W1971695868 @default.
• W1984176340 cites W1981023296 @default.
• W1984176340 cites W1983985175 @default.
• W1984176340 cites W1989649932 @default.
• W1984176340 cites W1992336474 @default.
• W1984176340 cites W1993179214 @default.
• W1984176340 cites W2002488838 @default.
• W1984176340 cites W2005100357 @default.
• W1984176340 cites W2007683100 @default.
• W1984176340 cites W2017902030 @default.
• W1984176340 cites W2018133517 @default.
• W1984176340 cites W2024272753 @default.
• W1984176340 cites W2024739169 @default.
• W1984176340 cites W2033498478 @default.
• W1984176340 cites W2039629489 @default.
• W1984176340 cites W2049524204 @default.
• W1984176340 cites W2057619903 @default.
• W1984176340 cites W2057720246 @default.
• W1984176340 cites W2058248915 @default.
• W1984176340 cites W2065376561 @default.
• W1984176340 cites W2065378127 @default.
• W1984176340 cites W2069720072 @default.
• W1984176340 cites W2078901357 @default.
• W1984176340 cites W2086524338 @default.
• W1984176340 cites W2091673674 @default.
• W1984176340 cites W2092356580 @default.
• W1984176340 cites W2100246616 @default.
• W1984176340 cites W2103178229 @default.
• W1984176340 cites W2104572704 @default.
• W1984176340 cites W93019692 @default.
• W1984176340 doi "https://doi.org/10.1074/jbc.m305381200" @default.
• W1984176340 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12871960" @default.
• W1984176340 hasPublicationYear "2003" @default.
• W1984176340 type Work @default.
• W1984176340 sameAs 1984176340 @default.
• W1984176340 citedByCount "6" @default.
• W1984176340 countsByYear W19841763402012 @default.
• W1984176340 countsByYear W19841763402014 @default.
• W1984176340 crossrefType "journal-article" @default.
• W1984176340 hasAuthorship W1984176340A5037677450 @default.
• W1984176340 hasAuthorship W1984176340A5053608387 @default.
• W1984176340 hasAuthorship W1984176340A5056746618 @default.
• W1984176340 hasAuthorship W1984176340A5061438758 @default.
• W1984176340 hasBestOaLocation W19841763401 @default.
• W1984176340 hasConcept C119062480 @default.
• W1984176340 hasConcept C12554922 @default.
• W1984176340 hasConcept C158617107 @default.
• W1984176340 hasConcept C184235292 @default.
• W1984176340 hasConcept C185592680 @default.
• W1984176340 hasConcept C55493867 @default.
• W1984176340 hasConcept C86803240 @default.
• W1984176340 hasConcept C95444343 @default.
• W1984176340 hasConcept C97029542 @default.
• W1984176340 hasConceptScore W1984176340C119062480 @default.
• W1984176340 hasConceptScore W1984176340C12554922 @default.
• W1984176340 hasConceptScore W1984176340C158617107 @default.
• W1984176340 hasConceptScore W1984176340C184235292 @default.
• W1984176340 hasConceptScore W1984176340C185592680 @default.
• W1984176340 hasConceptScore W1984176340C55493867 @default.
• W1984176340 hasConceptScore W1984176340C86803240 @default.
• W1984176340 hasConceptScore W1984176340C95444343 @default.
• W1984176340 hasConceptScore W1984176340C97029542 @default.
• W1984176340 hasIssue "39" @default.
• W1984176340 hasLocation W19841763401 @default.
• W1984176340 hasOpenAccess W1984176340 @default.
• W1984176340 hasPrimaryLocation W19841763401 @default.
• W1984176340 hasRelatedWork W1589334735 @default.
• W1984176340 hasRelatedWork W1717645404 @default.
• W1984176340 hasRelatedWork W1990580490 @default.
• W1984176340 hasRelatedWork W2000302322 @default.
• W1984176340 hasRelatedWork W2025794474 @default.
• W1984176340 hasRelatedWork W2057805673 @default.
• W1984176340 hasRelatedWork W2083259022 @default.
• W1984176340 hasRelatedWork W2097020042 @default.
• W1984176340 hasRelatedWork W2164785233 @default.
• W1984176340 hasRelatedWork W900911122 @default.
• W1984176340 hasVolume "278" @default.
• W1984176340 isParatext "false" @default.
• W1984176340 isRetracted "false" @default.
• W1984176340 magId "1984176340" @default.
• W1984176340 workType "article" @default.